Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 18.08.2025 1 Arch Pediatr 2 BMJ 3 Clin Infect Dis 3 J Infect 5 J Infect Dis 1 J Virol 3 Lancet 1 MMWR Morb Mortal Wkly Rep 1 Nat Med 1 PLoS Comput Biol 3 PLoS One 1 Proc Natl Acad Sci U S A 27 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Pediatr

1. HOEN B
   Recent and important updates to the French meningococcal vaccination strategy.
   Arch Pediatr. 2025 Aug 12:361-362. doi: 10.1016/j.arcped.2025.
   PubMed        
   
   

   
   BMJ

2. TANNE JH
   Vinay Prasad reinstated to FDA vaccines role, 14 days after resignation.
   BMJ. 2025;390:r1723.
   PubMed        
   
   
3. PATERLINI M
   Vaccine sceptics appointed to advise Italian government on immunisation.
   BMJ. 2025;390:r1710.
   PubMed        
   
   

   
   Clin Infect Dis

4. RAYENS E, Sy LS, Qian L, Wu J, et al
   Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged >/=50 years.
   Clin Infect Dis. 2025 Aug 9:ciaf440. doi: 10.1093.
   PubMed         Abstract available
   
   
5. RON R, Diaz-Garcia C, Sendagorta E, Cabello-Ubeda A, et al
   A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.
   Clin Infect Dis. 2025 Aug 6:ciaf435. doi: 10.1093.
   PubMed         Abstract available
   
   
6. SCHNYDER JL, Haggenburg S, Garcia Garrido HM, Reiners A, et al
   Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV - 3-year follow-up of a pr
   Clin Infect Dis. 2025 Aug 6:ciaf438. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

7. LADHANI SN, Mandal S, Mohammed H, Saunders J, et al
   The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: a review of the evidence and knowledge gaps.
   J Infect. 2025 Aug 7:106582. doi: 10.1016/j.jinf.2025.106582.
   PubMed         Abstract available
   
   
8. JANANI L, Munro APS, Wright A, Aley PK, et al
   Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
   J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
   PubMed         Abstract available
   
   
9. JEGEDE B, Zhou Y, Hawksworth H, Hui DS, et al
   Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged >/=50 years with a history of herpes zoster: a phase 3, randomized controlled trial.
   J Infect. 2025 Aug 6:106573. doi: 10.1016/j.jinf.2025.106573.
   PubMed         Abstract available
   
   

   
   J Infect Dis

10. CONSTENLA D, Lonnet G, Aris E, Ramsanjay RK, et al
    Real-world effectiveness of the adjuvanted recombinant zoster vaccine in >/=50-year-old adults with autoimmune diseases.
    J Infect Dis. 2025 Aug 11:jiaf395. doi: 10.1093.
    PubMed         Abstract available
    
    
11. XU W, Antonello J, Nguyen J, Ma C, et al
    Low intrinsic killing activity and no impact of its positivity on phase 3 pneumococcal vaccine adult studies.
    J Infect Dis. 2025 Aug 11:jiaf427. doi: 10.1093.
    PubMed         Abstract available
    
    
12. ESPERSEN C, Johansen ND, Modin D, Janstrup KH, et al
    Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trial.
    J Infect Dis. 2025 Aug 13:jiaf420. doi: 10.1093.
    PubMed         Abstract available
    
    
13. CHUANG YM, Ledizet M, Mattessich M, Fikrig E, et al
    A multivalent peptide vaccine against malaria, targeting Plasmodium CSP and mosquito AgTRIO.
    J Infect Dis. 2025 Aug 13:jiaf432. doi: 10.1093.
    PubMed         Abstract available
    
    
14. JATT LP, Gillespie KM, Van P, Hoffman SL, et al
    Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection.
    J Infect Dis. 2025 Aug 14:jiaf435. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

15. GUO S, Ru Y, Zhang H, Xue J, et al
    An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.
    J Virol. 2025 Aug 14:e0047825. doi: 10.1128/jvi.00478.
    PubMed         Abstract available
    
    

    
    Lancet

16. KULKARNI PS, Potey AV, Kapse D, Bhamare C, et al
    Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
    Lancet. 2025;406:627-635.
    PubMed         Abstract available
    
    
17. WAGNER J
    Respiratory syncytial virus vaccine effectiveness.
    Lancet. 2025;406:599.
    PubMed        
    
    
18. PAYNE AB, Mitchell PK, Watts JA, Link-Gelles R, et al
    Respiratory syncytial virus vaccine effectiveness - Authors' reply.
    Lancet. 2025;406:599-600.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

19. PINGALI C, Yankey D, Elam-Evans LD, Trahan A, et al
    Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:466-472.
    PubMed         Abstract available
    
    

    
    Nat Med

20. WAINBERG ZA, Weekes CD, Furqan M, Kasi PM, et al
    Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
    Nat Med. 2025 Aug 11. doi: 10.1038/s41591-025-03876.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

21. SCIANNA M, Gallotti R, Tizzoni M, Artime O, et al
    Comparing the effectiveness of ring and block-vaccination strategies on networks.
    PLoS Comput Biol. 2025;21:e1013274.
    PubMed         Abstract available
    
    

    
    PLoS One

22. WYPLOSZ B, Grenier B, Roche N, Roubille F, et al
    Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France.
    PLoS One. 2025;20:e0329703.
    PubMed         Abstract available
    
    
23. TOUZET H, Privault S, Ward JK
    The role of professional socialisation in confidence in vaccines and vaccination decision-makers: Insights from a large multi-wave survey in France.
    PLoS One. 2025;20:e0328548.
    PubMed         Abstract available
    
    
24. PRASERT K, Praphasiri P, Ditsungnoen D, Srichaijaroonpong S, et al
    Perceptions of influenza and SARS-CoV-2 vaccination among health care personnel in Thailand, 2024.
    PLoS One. 2025;20:e0329473.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

25. LIN X, Cottrell CA, Kalyuzhniy O, Tingle R, et al
    Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.
    Proc Natl Acad Sci U S A. 2025;122:e2510163122.
    PubMed         Abstract available
    
    

    
    Vaccine

26. COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al
    Corrigendum to "Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children" [Vaccine 61 (2025) 127245].
    Vaccine. 2025;62:127584.
    PubMed        
    
    
27. ASHRAF M, Stein AN, Youhanna J, Rockman S, et al
    The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness.
    Vaccine. 2025;62:127393.
    PubMed         Abstract available
    
    
28. BAUR C, Saperstein SL, Griffis RL, Vazquez C, et al
    Implementing a co-design approach to facilitate a COVID-19 vaccination rapid response.
    Vaccine. 2025;62:127585.
    PubMed         Abstract available
    
    
29. LINDSEY KM, Farrell Z, Tutino R, Kowalski-Dobson T, et al
    From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.
    Vaccine. 2025;62:127593.
    PubMed         Abstract available
    
    
30. ARAKAWA T, Uefuji H, Tamaki Y, Oogai S, et al
    Corrigendum to "B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded alpha-helical coiled coil protects piglets from porcine edema disease" [Vaccine 61 (2025) 127140].
    Vaccine. 2025;62:127582.
    PubMed        
    
    
31. BORG A, Goulding M, Minkah P, Perrone D, et al
    Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.
    Vaccine. 2025;60 Suppl 1:127586.
    PubMed         Abstract available
    
    
32. JAYARAJ VJ, Husin M, Tok PSK, Ismail MZH, et al
    Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial.
    Vaccine. 2025;62:127569.
    PubMed         Abstract available
    
    
33. LI J, Zhao D, Zi T, Huang R, et al
    Evolving trends in HPV vaccination coverage among women aged 9-45 in Chengdu, China: insights from 2017 to 2023.
    Vaccine. 2025;62:127579.
    PubMed         Abstract available
    
    
34. CHEN Y, Jiang N, Jiao Y, Chen J, et al
    Analysis of HPV vaccination and influencing factors among 9-14-year-old girls in underdeveloped areas of northwestern China: A cross-sectional survey report on guardians.
    Vaccine. 2025;62:127568.
    PubMed         Abstract available
    
    
35. HORIKOSHI Y, Toizumi M
    Pediatric tuberculosis and BCG vaccine in Japan.
    Vaccine. 2025;62:127564.
    PubMed         Abstract available
    
    
36. IMHOF C, Liu S, Messchendorp AL, Sanders JF, et al
    The phenotype and functionality of spike-specific CD4(+) T cells after COVID-19 vaccination associates with time after transplantation in transplant recipients.
    Vaccine. 2025;62:127600.
    PubMed         Abstract available
    
    
37. NUZHATH T, Khobragade N, Regan AK, Pinkney JA, et al
    Pregnant women's perceptions of RSVpreF vaccine and Nirsevimab for infant RSV prevention.
    Vaccine. 2025;62:127590.
    PubMed         Abstract available
    
    
38. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    PubMed         Abstract available
    
    
39. NAHAR N, Parveen S, Gurley ES, Ghosh PK, et al
    Community willingness to participate in a Nipah vaccine trial in Bangladesh.
    Vaccine. 2025;62:127578.
    PubMed         Abstract available
    
    
40. ORTIZ-PRADO E, Kyriakidis NC, Lopez-Cortes A, Vasconez-Gonzalez J, et al
    Current and emerging Mpox vaccine strategies: A comprehensive review.
    Vaccine. 2025;62:127598.
    PubMed         Abstract available
    
    
41. VASILIADIS S, Cook J, Nissan K, Cook W, et al
    Vaccine misinformation among Arabic-speakers in Australia and the audience and appetite for a game-based intervention.
    Vaccine. 2025;62:127599.
    PubMed         Abstract available
    
    
42. HURLEY F, Balanuta MS, Flanagan P
    Barriers and facilitators associated with migrant parents' decisions regarding childhood vaccinations: A mixed methods systematic review.
    Vaccine. 2025;62:127588.
    PubMed         Abstract available
    
    
43. MCGEE RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, et al
    Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.
    Vaccine. 2025;60 Suppl 1:127587.
    PubMed         Abstract available
    
    
44. WEI H, Wang Y, Jiang S, Zhang X, et al
    The roles of tissue-resident memory T cells (TRMs) in diseases and vaccine development: A comprehensive review.
    Vaccine. 2025;62:127605.
    PubMed         Abstract available
    
    
45. LUVIRA V, Lawpoolsri S, Phumratanaprapin W, Jongkaewwattana A, et al
    Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).
    Vaccine. 2025;62:127601.
    PubMed         Abstract available
    
    
46. HUNTER OF, McClymont E, Lau O, Bettinger JA, et al
    Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortium.
    Vaccine. 2025;62:127594.
    PubMed         Abstract available
    
    
47. GAO L, Zhang X, Mo X, Sun Y, et al
    Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
    Vaccine. 2025;62:127596.
    PubMed         Abstract available
    
    
48. YAMEY G, Beyrer C
    The dismantling of the U.S. vaccine regulatory framework.
    Vaccine. 2025;62:127557.
    PubMed        
    
    
49. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Corrigendum to "Social processes, practical issues, and COVID-19 vaccination among hesitant adults" [Vaccine 41(35) (2023) 5150-5158].
    Vaccine. 2025;62:127583.
    PubMed        
    
    
50. BHAT S, Basak P, Verma S, Siddiqui K, et al
    Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination.
    Vaccine. 2025;62:127604.
    PubMed         Abstract available
    
    
51. ROBERTS C, Top KA, Henaff L, Tunis M, et al
    Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.
    Vaccine. 2025;62:127581.
    PubMed         Abstract available
    
    
52. VARMA A, Andrews NJ, Carazo S, Walter K, et al
    Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.
    Vaccine. 2025;62:127567.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.